@article{472b0b73df034ea6902b558b4d0bfc7b,
title = "Case series of sebelipase alfa hypersensitivity reactions and successful sebelipase alfa rapid desensitization",
abstract = "Allergic immune-mediated hypersensitivity reactions are known potential complications of enzyme replacement therapy. Sebelipase alfa, recombinant lysosomal acid lipase (LAL), is a potentially life-altering treatment for patients with LAL deficiency. There is very little information on the diagnosis and management of immediate hypersensitivity reactions to this drug. Here we present three unique cases of hypersensitivity reactions to sebelipase alfa, spanning a broad age spectrum from infancy to adulthood, each managed with successful rapid desensitization.",
keywords = "allergy, anaphylaxis, desensitization, enzyme replacement therapy, hypersensitivity, sebelipase alfa",
author = "Huffaker, {Michelle F.} and Liu, {Anne Y.} and Enns, {Gregory M.} and Suresh Vijay and Amor, {Antonio J.} and Adkinson, {N. Franklin}",
note = "Funding Information: M.F.H., A.Y.L., and A.J.A. declare that they have no conflict of interest. G.M.E. received funding for the conduct of clinical studies from Alexion Pharmaceuticals, Inc. S.V. has been a consultant for Alexion Pharmaceuticals, Inc., received honoraria and travel grants from Alexion Pharmaceuticals, Inc. N.F.A. has been a consultant for Alexion Pharmaceuticals, Inc. Funding Information: information Alexion Pharmaceuticals, Inc.We are indebted to Thu Quan (Department of Pediatrics, Stanford University) for coordinating the implementation of the desensitization protocol for case 3 and to Joan Bartra and Jaime S?nchez-L?pez (Department of Pneumology and Allergology, Hospital Clinic Barcelona) for the performance of the allergy studies and the design of desensitization protocol for case 1. This is an analysis of patient cases that were enrolled in studies sponsored by Alexion Pharmaceuticals, Inc. Although Alexion Pharmaceuticals, Inc., provided medical review and confirmed some data for the cases described in this article, the authors had full editorial control of the content of this article. Publisher Copyright: {\textcopyright} 2019 The Authors. Journal of Inherited Metabolic Disease published by John Wiley & Sons Ltd on behalf of SSIEM.",
year = "2019",
month = jun,
day = "1",
doi = "10.1002/jmd2.12066",
language = "English (US)",
volume = "49",
pages = "30--36",
journal = "JIMD Reports",
issn = "2192-8304",
publisher = "Springer Berlin",
number = "1",
}